Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C9*3 allele?

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 3, 2006, Pages 298-301

  Rodrigues, A David ^a   Yang, Zheng ^a   Chen, Cliff ^a   Pray, Devin ^a   Kim, Sean ^a   Sinz, Michael ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYTOCHROME P450 2C9; FLUCONAZOLE; SULFAPHENAZOLE;

AREA UNDER THE CURVE; CONCENTRATION RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; FIRST PASS EFFECT; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; HOMOZYGOSITY; HUMAN; LETTER; PRIORITY JOURNAL;

ALLELES; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; PYRAZOLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES;

EID: 33748070195     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.05.009     Document Type: Letter

References (15)

1. Lundblad M.S., Ohlsson S., Johansson P., Lafolie P., and Eliasson E. Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3. Clin Pharmacol Ther 79 (2006) 287-288
2. Stempak D., Bukaveckas B.L., Linder M., Koren G., and Baruchel S. Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient. Clin Pharmacol Ther 78 (2005) 309-310
3. Rodrigues A.D. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?. Drug Metab Dispos 33 (2005) 1567-1575
4. Tang C., Shou M., Rushmore T.H., Mei Q., Sandhu P., Woolf E.J., et al. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 11 (2001) 223-235
5. Kirchheiner J., Stormer E., Meisel C., Steinbach N., Roots I., and Brockmoller J. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 13 (2003) 473-480
6. Davies N.M., McLachlan A.J., Day R.O., and Williams K.M. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38 (2000) 225-242
7. Tang C., Shou M., Mei Q., Rushmore T.H., and Rodrigues A.D. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther 293 (2000) 453-459
8. Sandberg M., Yasar U., Strömberg P., Höög J.O., and Eliasson E. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol 54 (2002) 423-429
9. 14C]celecoxib in healthy male volunteers. Drug Metab Dispos 28 (2000) 308-314
10. Brenner S.S., Herrlinger C., Dilger K., Murdter T.E., Hofmann U., Marx C., et al. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin Pharmacokinet 42 (2003) 283-292
11. Luo G., Cunningham M., Kim S., Burn T., Lin J., Sinz M., et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30 (2002) 795-804
12. McGinnity D.F., Tucker J., Trigg S., and Riley R.J. Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. Drug Metab Dispos 33 (2005) 1700-1707
13. Gasparini G., Meo S., Comella G., Stani S.C., Mariani L., Gamucci T., et al. The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates. Cancer J 11 (2005) 209-216
14. Bensen W.G., Fiechtner J.J., McMillen J.I., Zhao W.W., Yu S.S., Woods E.M., et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 74 (1999) 1095-1105
15. Wirth L.J., Haddad R.I., Lindeman N.I., Zhao X., Lee J.C., Joshi V.A., et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 6976-6981